Table 2.

Clinical outcomes.

Variable
Partial response	5 (9.8%)
Stable disease	13 (25.5%)
Progression disease	33 (64.7%)
Disease control rate	35.3%
Time to response (months) †	2.5 (2.1–8.3)
Progression-free survival (months)	2.1 (95% CI 1.7–2.4)
Overall survival (months)	6.9 (95% CI 5.4–8.3)

Patients, n = 51, ^† Evaluation in five patients with a partial response.